

# Evolut Clinical Guideline 3013 for Libtayo™ (cemiplimab-rwlc)

<b>Guideline Number:</b> Evolut_CG_3013	<b><u>Applicable Codes</u></b>	
<b><i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i></b> <b><i>© 2018 - 2025 Evolut. All rights Reserved.</i></b>		
<b>Original Date:</b> October 2018	<b>Last Revised Date:</b> February 2025	<b>Implementation Date:</b> February 2025

## TABLE OF CONTENTS

<b>STATEMENT .....</b>	<b>2</b>
PURPOSE .....	2
<b>INDICATIONS .....</b>	<b>2</b>
BASAL CELL CARCINOMA .....	2
CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC).....	2
NON-SMALL CELL LUNG CANCER (NSCLC) .....	2
<b>CONTRAINDICATIONS/WARNINGS .....</b>	<b>3</b>
<b>EXCLUSION CRITERIA .....</b>	<b>3</b>
<b>CODING AND STANDARDS .....</b>	<b>4</b>
CODES.....	4
APPLICABLE LINES OF BUSINESS .....	4
<b>POLICY HISTORY .....</b>	<b>4</b>
<b>LEGAL AND COMPLIANCE .....</b>	<b>4</b>
GUIDELINE APPROVAL .....	4
Committee.....	4
DISCLAIMER .....	4
<b>REFERENCES.....</b>	<b>6</b>

## STATEMENT

### Purpose

To define and describe the accepted indications for Libtayo (cemiplimab-rwlc) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

## INDICATIONS

**Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided**

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

### Basal Cell Carcinoma

- Libtayo (cemiplimab-rwlc) may be used as a single agent, in members with locally advanced/recurrent/metastatic basal cell carcinoma, who are not candidates for surgery and/or radiation therapy.

### Cutaneous Squamous Cell Carcinoma (CSCC)

- The member has unresectable locally advanced or metastatic Cutaneous Squamous Cell Carcinoma and is not a candidate for curative surgery and/or curative radiation AND
- Libtayo (cemiplimab-rwlc) is being used as a single agent AND
- The member has not received prior therapy with another immune checkpoint inhibitor (e.g., pembrolizumab).

### Non-Small Cell Lung Cancer (NSCLC)

- The member has locally advanced, recurrent, or metastatic NSCLC, negative for the following actionable molecular markers ALK, EGFR, and ROS-1 (ALK, EGFR, and ROS-1 not required for squamous histology), and has not experienced disease progression on prior Immune Checkpoint Inhibitor therapy, including Keytruda (pembrolizumab), Opdivo (nivolumab), OR Tecentriq (atezolizumab) AND the following criteria are met:

- Libtayo (cemiplimab-rwlc) will be used as first line therapy as a single agent if PD-L1 is greater than or equal to 50%.
- Libtayo (cemiplimab-rwlc) may be used in combination with platinum-based chemotherapy for the first line treatment of adult members with non-small cell lung cancer (NSCLC) with no EGFR/ALK/ROS1 genomic aberrations (ALK, EGFR, and ROS-1 not required for squamous histology) in the following clinical scenarios:
  - Locally advanced Non-Small Cell Lung Cancer for which the members are not a candidate for surgical resection and also not a candidate for definitive chemoradiation OR,
  - Metastatic Non-Small Cell Lung Cancer

## CONTRAINDICATIONS/WARNINGS

- None

## EXCLUSION CRITERIA

- Libtayo (cemiplimab-rwlc) is used after disease progression with the same regimen or prior treatment with an Immune Checkpoint Inhibitor therapy [e.g., Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab)].
- Dosing exceeds single dose limit of Libtayo (cemiplimab-rwlc) 350 mg.
- Investigational use of Libtayo (cemiplimab-rwlc) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.

- That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

## CODING AND STANDARDS

### Codes

- J9119 - Injection, cemiplimab-rwlc, 1 mg

### Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children's Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

## POLICY HISTORY

Date	Summary
February 2025	<ul style="list-style-type: none"> <li>● Converted to new Evolent guideline template</li> <li>● This guideline replaces UM ONC_1089 Libtayo (cemiplimab-rwlc)</li> </ul>
February 2024	<ul style="list-style-type: none"> <li>● Updated verbiage in single-agent use and in combination with platinum-based chemotherapy under NSCLC indication section</li> </ul>

## LEGAL AND COMPLIANCE

### Guideline Approval

#### *Committee*

Reviewed / Approved by Evolent Specialty Clinical Guideline Review Committee

### Disclaimer



*Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.*

## REFERENCES

1. Gogishvili M, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. *Nat Med*. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y.
2. Sezer A, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet*. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2.
3. Migden MR, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. *N Engl J Med*. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131.
4. Libtayo prescribing information. Regeneron Pharmaceuticals, Inc. Tarrytown, NY 2024.
5. Clinical Pharmacology Elsevier Gold Standard 2025.
6. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
7. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
8. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
9. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
10. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.